Skip to Main Content

Author Details

Claude Gardin
Avicenne Hospital
1990
114
43
Antoine Forget (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
37085611UBTF tandem duplications define a distinct subtype of adult de novo acute myeloid leukemia.Leukemia2023
34615986Machine learning identifies the independent role of dysplasia in the prediction of response to chemotherapy in AML.Leukemia2022
35443031Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study.Blood2022
35474100Cystine uptake inhibition potentiates front-line therapies in acute myeloid leukemia.Leukemia2022
36431240Preclinical Evaluation of a Novel Small Molecule Inhibitor of LIM Kinases (LIMK) CEL_Amide in Philadelphia-Chromosome Positive (<i>BCR::ABL+</i>) Acute Lymphoblastic Leukemia (ALL).J Clin Med2022
36570694Relative Mitochondrial Priming Predicts Survival in Older AML Patients Treated Intensively.Hemasphere2022
32871585A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia.Blood2021
33881523Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study.Blood2021
34410352Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy.Blood2021
33373830Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 CEL_Amide in FLT3-ITD mutated Acute Myeloblastic Leukemia (AML) cells.Leuk Res2021
32380535Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results.Blood Adv2020
31204545Insights into the cellular pharmacological properties of the BET-inhibitor OTX015/MK-8628 (birabresib), alone and in combination, in leukemia models.Leuk Lymphoma2019
31751766BET inhibitors impair leukemic stem cell function only in defined oncogenic subgroups of acute myeloid leukaemias.Leuk Res2019
30076173Gemtuzumab ozogamicin for <i>de novo</i> acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial.Haematologica2019
28838276Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+).Leuk Lymphoma2018
30026341Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group.Haematologica2018
30025278Outcomes and mutational analysis of patients with lower-risk non-del5q myelodysplastic syndrome treated with antithymocyte globulin with or without ciclosporine A.Leuk Res2018
28034993Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the <i>Groupe Francophone Des Myélodysplasies</i>.Haematologica2017
28286907Hypomethylating Agents as a Therapy for AML.Curr Hematol Malig Rep2017
28541716Investigational BET bromodomain protein inhibitors in early stage clinical trials for acute myelogenous leukemia (AML).Expert Opin Investig Drugs2017
26922775Efficacy of Azacitidine in autoimmune and inflammatory disorders associated with myelodysplastic syndromes and chronic myelomonocytic leukemia.Leuk Res2016
26660429An update of current treatments for adult acute myeloid leukemia.Blood2016
26350487Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study.Rheumatology (Oxford)2016
26500139Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion.Leukemia2016
27229713A randomized phase II trial of azacitidine +/- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents.Haematologica2016
27484914HBME-1 is expressed by erythroid precursors in early maturation stage and can be a valuable tool for evaluation of dyserythropoiesis in bone marrow core biopsy specimens.J Clin Pathol2016
27337291Autoimmune and inflammatory diseases associated with chronic myelomonocytic leukemia: A series of 26 cases and literature review.Leuk Res2016
26795084Imatinib Increases Serum Creatinine by Inhibiting Its Tubular Secretion in a Reversible Fashion in Chronic Myeloid Leukemia.Clin Lymphoma Myeloma Leuk2016
25524177Azacitidine for the treatment of relapsed and refractory AML in older patients.Leuk Res2015
26486081IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association.Oncotarget2015
26017030Incidence of ATRX mutations in myelodysplastic syndromes, the value of microcytosis.Am J Hematol2015
25989842BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells.Oncotarget2015
25735917Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.Leuk Res2015
25552703Impact of additional genetic alterations on the outcome of patients with NPM1-mutated cytogenetically normal acute myeloid leukemia.Haematologica2015
25601157Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction.Leuk Res2015
24375487Azacitidine in untreated acute myeloid leukemia: a report on 149 patients.Am J Hematol2014
25333797Aseptic muscular abscesses associated with myelodysplastic syndrome.Eur J Dermatol2014
23248249Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older.J Clin Oncol2013
23831922The prognosis of CALM-AF10-positive adult T-cell acute lymphoblastic leukemias depends on the stage of maturation arrest.Haematologica2013
23749683Outcome of older patients with acute myeloid leukemia in first relapse.Am J Hematol2013
23584440Matched unrelated or matched sibling donors result in comparable outcomes after non-myeloablative HSCT in patients with AML or MDS.Bone Marrow Transplant2013
22145959Infectious complications in adult acute myeloid leukemia: analysis of the Acute Leukemia French Association-9802 prospective multicenter clinical trial.Leuk Lymphoma2012
22730526Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort.Blood2012
22647869Outcome of treatment after first relapse in younger adults with acute myeloid leukemia initially treated by the ALFA-9802 trial.Leuk Res2012
22289988Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association.Leukemia2012
22390719Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure.Br J Haematol2012
22426749Evaluation of allogeneic hematopoietic SCT in younger adults with adverse karyotype AML.Bone Marrow Transplant2012
22072535Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50-70-year old: a phase 1/2 study of the acute leukemia French association.Am J Hematol2012
22129478Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia.Leuk Res2012
22177456Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?Leuk Res2012
  • 1 - 50 of 114

Recommended Authors

Curtis A Lachowiez
University of Texas MD Anderson Cancer Center
Career Start Year 2017
Number of shared co-authors 0
Justin M Watts
University of Miami, Sylvester Comprehensive Cancer Center
Career Start Year 2014
Number of shared co-authors 4
Uma Borate
The Ohio State University
Career Start Year 2008
Number of shared co-authors 1
Friedrich St??lzel
University Hospital TU Dresden
Career Start Year 2008
Number of shared co-authors 8
Courtney D DiNardo
UT MD Anderson Cancer Center
Career Start Year 2007
Number of shared co-authors 7
Felicitas Thol
Hannover Medical School
Career Start Year 2007
Number of shared co-authors 6
Marlise R Luskin
Dana-Farber Cancer Institute
Career Start Year 2005
Number of shared co-authors 2
Ronan Swords
Oregon Health and Science University
Career Start Year 2004
Number of shared co-authors 0
Naseema Gangat
Mayo Clinic
Career Start Year 2004
Number of shared co-authors 1
Tara L Lin
University of Kansas Medical Center
Career Start Year 2004
Number of shared co-authors 0
Daniel A Pollyea
University of Colorado Division of Hematology
Career Start Year 2004
Number of shared co-authors 1
Thomas Ernst
Universitatsklinikum Jena
Career Start Year 2002
Number of shared co-authors 1
Christopher S Hourigan
and Blood Institute, National Institutes of Health
Career Start Year 2001
Number of shared co-authors 1
Guillermo Garcia-Manero
MD Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 5
Farhad Ravandi
University of Texas M.D. Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 7
Luca Malcovati
University of Pavia & S. Matteo Hospital
Career Start Year 1997
Number of shared co-authors 7
Bruno C Medeiros
AbbVie Inc.
Career Start Year 1996
Number of shared co-authors 1
Timothy S Pardee
Comprehensive Cancer Center of Wake Forest Baptist Health, Medical Center Boulevard
Career Start Year 1995
Number of shared co-authors 6
David A Rizzieri
Duke University Medical Center
Career Start Year 1995
Number of shared co-authors 8
Michael Heuser
Hannover Medical School
Career Start Year 1993
Number of shared co-authors 7
Gautam Borthakur
MD Anderson Cancer Center
Career Start Year 1992
Number of shared co-authors 4
Michael W Becker
James P. Wilmot Cancer Institute, University of Rochester Medical Center Rochester
Career Start Year 1992
Number of shared co-authors 0
Jorge Cortes
Georgia Cancer Center
Career Start Year 1991
Number of shared co-authors 8
Peter Westervelt
Washington University School of Medicine
Career Start Year 1990
Number of shared co-authors 1
Jerald P Radich
Fred Hutchinson Cancer Center
Career Start Year 1989
Number of shared co-authors 2
Daniel J DeAngelo
Dana-Farber Cancer Institute
Career Start Year 1989
Number of shared co-authors 9
Richard M Stone
Dana Farber Cancer Institute
Career Start Year 1986
Number of shared co-authors 12
Torsten Haferlach
Taussig Cancer Institute, Cleveland Clinic
Career Start Year 1983
Number of shared co-authors 9
Hagop Kantarjian
The University of Texas MD Anderson Cancer Center
Career Start Year 1982
Number of shared co-authors 8
Martin S Tallman
Memorial Sloan-Kettering Cancer Center
Career Start Year 1982
Number of shared co-authors 6

Collaborators

Herv?? Dombret
Institut de Recherche Saint-Louis, Universite de Paris
Co-authored papers 60
Lionel Ad??s
Assistance Publique des Hopitaux de Paris (AP-HP)
Co-authored papers 35
Claude Preudhomme
Lille University Hospital, INSERM UMR-S7, CNRS UMR9020, Lille University.
Co-authored papers 35
Emmanuel Raffoux
Universite Paris Diderot
Co-authored papers 32
Raphael Itzykson
Universite Paris Cite, INSERM, CNRS
Co-authored papers 23
Thorsten Braun
Centre Hospitalier Universitaire Hopital Avicenne
Co-authored papers 19
Thomas Cluzeau
Universite Nice Cote d'azur, CHU de Nice
Co-authored papers 7
Jean-Baptiste Micol
INSERM U7, Universite Paris-Saclay
Co-authored papers 7
Emmanuelle Clappier
Saint-Louis Hospital
Co-authored papers 6
Jeannig Berrou
Universite Paris Cite, Institut de Recherche Saint-Louis
Co-authored papers 5
Matthieu Duchmann
Assistance Publique-Hopitaux de Paris, Universite de Paris
Co-authored papers 4
Alexandre Puissant
Universite de Paris, INSERM, CNRS
Co-authored papers 3
Jean Soulier
University of Paris
Co-authored papers 3
Cl??mentine Chauvel
Universite Paris Cite, INSERM, CNRS
Co-authored papers 2
Reinaldo Dal Bello
Universite Paris Cite, INSERM, CNRS
Co-authored papers 2
Justine Penneroux
Universite Paris Cite, INSERM, CNRS
Co-authored papers 2
Christoph R??llig
Hopp Children's Cancer Center (KiTZ)
Co-authored papers 1
Kimberly Stegmaier
Dana-Farber Cancer Institute
Co-authored papers 1
Nina Fenouille
Universite Paris Cite, INSERM, CNRS
Co-authored papers 1
Bryann Pardieu
Universite Paris Cite, INSERM, CNRS
Co-authored papers 1
Hsin-Chieh Wu
Chaoyang University of Technology
Co-authored papers 1
Loic Vasseur
Universite Paris Cite, INSERM, CNRS
Co-authored papers 1
Brian J P Huntly
University of Cambridge
Co-authored papers 1
Camille Lobry
INSERM U1170, Universite Paris Saclay
Co-authored papers 1
Justine Pasanisi
Universite Paris Cite, INSERM, CNRS
Co-authored papers 1
Camille Vaganay
Universite Paris Cite, INSERM, CNRS
Co-authored papers 1
Chaima Benaksas
Universite Paris Cite, INSERM, CNRS
Co-authored papers 1
Gabriela Alexe
Dana-Farber Cancer Institute
Co-authored papers 1
Fran??ois Fenaille
Universite Paris-Saclay
Co-authored papers 1
Patrick Auberger
Universite Cote d'Azur, INSERM U5
Co-authored papers 1
Release 1.2